Abdominal lymph node recurrence from colorectal cancer: Resection should be considered as a curative treatment in patients with controlled disease

BackgroundLymph node recurrences (LNR) from colorectal cancer (CRC) still represent a therapeutic challenge, as standardized recommendations have yet to be established. The aim of this study was to analyze short- and long-term oncological outcomes following resection of LNR from CRC.MethodsAll patients with previously resected CRC who underwent histopathologically confirmed LNR resection in 3 tertiary referral centers between 2010 and 2017 were reviewed. Short- and long-term outcomes were analyzed, mainly recurrence-free and overall survival. Further recurrences following LNR resection were also analyzed.ResultsOverall, 18 patients were included. Primary CRC was left-sided in 16 (89%) patients, staged T3-4 in 15 (83%), N+ in 14 (78%) and presented with synchronous metastases in 8 (43%). Median time interval between primary CRC and LNR resections was 31 months. Performed lymphadenectomies were aortocaval (n = 10), pelvic (n = 7), in hepatic pedicle (n = 3) and mesenteric (n = 1). Four patients had associated liver metastases resection. Three (17%) presented with postoperative complications, of which one Clavien-Dindo 3. Fourteen (78%) patients presented with further recurrences after a mean delay of 9 months, with 36% of patients presenting with early (<6 months) recurrence. Five (36%) patients could undergo secondary recurrence resection and 3 (21%) patients radiotherapy. Median overall survival following LNR resection reached 44 months.ConclusionsCurrent results suggest that LNR resection is feasible and associated with improved survival, in selected patients. Longer time interval between primary CRC resection and LNR occurrence appeared to be a favorable prognostic factor whereas multisite recurrence appeared to be associated with impaired long-term survival.     

进展期胃癌的淋巴结转移特点及其临床意义

目的探讨进展期胃癌的淋巴结转移特点及临床意义。方法对2002年4月至2003年7月期间进行胃癌根治淋巴结清扫手术的91例患者的手术切除标本进行解剖，收集切除的淋巴结，逐枚进行病理组织学和免疫组织化学检查，判断淋巴结是否转移并计算淋巴结转移率。分析淋巴结转移率与肿瘤大小、TNM分期、Borrmann分型、肿瘤部位和淋巴结清扫范围等方面的关系。结果91例胃癌患者中淋巴结转移阳性63例（69．2％）。共收获3149枚淋巴结，平均每例34．6枚。肿瘤直径小于3cm者淋巴结转移率较3cm以上者低（P〈0．05）。TNM分期中Ⅲa和Ⅳ期患者淋巴结转移率均为100％，其转移度在30．3％～58．4％之间，较Ⅰ、Ⅱ期者高（P〈0．001）；Borrmann分型中Ⅲ型病例的淋巴结转移率（79．6％）较其他型患者高，而Ⅳ型患者淋巴结转移度（35．3％）最高（P〈0．05）。施行D3淋巴结清扫手术患者的淋巴结转移率和转移度（88．2％、38．0％）均高于D1、D2术患者（P〈0．05）。17例（18．7％）患者常规病理检查发现有183枚淋巴结微转移，肿瘤各部位与淋巴结微转移的关系差异无统计学意义（P〉0．05）。近端胃癌淋巴结转移主要在第1、2、3、5、7、8、9、12、13和16组，以8组转移度为最高（68．1％）；中部胃癌淋巴结转移主要在第1、3、7、12、13和16组，其中最高转移度为第3组（47．6％）；远侧胃癌淋巴结转移主要见于1、2．3、5、6、12、13和16组，其中第16组转移度为最高（83．3％）。结论淋巴结转移率和转移度与胃癌的恶性程度密切相关，因此D3淋巴结清扫手术对某些进展期胃癌患者值得考虑使用。     

Lymph Node Dissection Impact on Staging and Survival of Extrahepatic Cholangiocarcinomas,Based on U.S. Population Data

Cholangiocarcinomas (CC) frequently demonstrate lymphatic spread. We investigated lymph node (LN) counts after resection of extrahepatic CC and survival based on the SEER 1973–2004 database. Out of 20,068 CC patients, 1,518 individuals were selected based on M0 stage and at least one LN examined. Primary cancer sites included gallbladder (29%), extrahepatic bile ducts (26%), and intrapancreatic/ampullary bile ducts (45%); 42% of patients were LN-positive. The median number of LNs examined was four (range 1–39). Median survival was 37 months for LN-negative and 16 months for LN-positive cancers. Multivariate prognostic variables were the number of positive LNs, primary site, age (all at p < 0.0001), gender (p = 0.002), size (p = 0.005), T category (p = 0.009), and total LN count (or number of negative LNs obtained, p = 0.01). The impact of total LN counts was seen in LN-negative (median survival, 1 vs 10 or more LNs examined: 27 vs 51 months, p = 0.002) and LN-positive disease (10 vs 22 months, p < 0.0001). Survival prediction of extrahepatic CCs is strongly influenced by total LN counts and numbers of negative LNs obtained. Although the resulting incremental benefit is small, dissection and examination of 10 or more LNs should be considered for curative intent resections.     

区域淋巴结廓清在胰头癌根治术中的应用

目的 探讨区域淋巴结廓清结合胰十二指肠切除术治疗胰头癌的有效性和安全性。方法 在常规胰十二指肠切除术(Whipple)基础上，进行区域淋巴结廓清，同时清除从腹腔动脉干至肠系膜下动脉的后腹膜组织，重点清除肠系膜根部淋巴结(14组)、肝十二指肠韧带内淋巴结(12组)、腹主动脉旁淋巴结(16组)、以及肝动脉旁(8组)、腹腔动脉旁(9组)淋巴结。结果 53例胰头癌病人施行了以区域淋巴结廓清为重点的胰头癌根治术，其中有3例合并切除了受浸润的一段肠系膜上静脉。手术无严重并发症发生，病人均痊愈出院。53例病人中有38例(72％)发生淋巴结转移，其中以胰头后(13组)、肠系膜根部(14组)发生率最高；14组淋巴结中各亚组转移率较为平均；发生第二站淋巴结转移的比例高达63％；肿瘤大小与淋巴结转移不成正比，小于2cm的肿瘤已经有第二站淋巴结的转移；术后1，2，3，5年生存率分别为70％，52．8％，26．7％，17．8％。结论 胰头癌的淋巴结转移呈现发生早、播散远和以肠系膜根部等部位为重点的特征，以区域淋巴结廓清为重点的胰头癌根治术能较为彻底地清除区域内淋巴结以及后腹膜组织，有助于保证手术的彻底性。     

胃癌10和11组淋巴结转移及其清扫

目的：研究胃癌脾门淋巴结(No．10)和脾动脉周围淋巴结(No．11)转移规律，进一步探讨No．10和11清扫的必要性和方法。方法：1991年-2000年132例行全胃切除，D2以上淋巴结清扫的胃癌患者，回顾性研究临床病理资料，包括性别、年龄、肿瘤部位、大小、浸润深度、病理类型、其他淋巴结转移等对No．10和11转移的影响，比较全胃切除和全胃联合脏器切除的并发症发生率。结果：胃癌具有较高的No．10或11淋巴结转移率(18．9％)，Logistic回归分析表明，胃癌部位、病理类型、浸润深度和大小弯淋巴结转移五项临床病理指标影响No．10和U转移率。联合脏器切除的并发症发生率(32％)明显高于单纯全胃切除(11．2％)，联合肢体尾切除增加肠下脓肿发生率，而脾切除并不增加全胃切除的危险性。结论：No．10和11在胃癌有较高的转移率和特定的转移规律，预防性和治疗性的清扫实属必要，联合左侧肢体尾加脾切除增加手术危险性，应严格掌握的适应证。而保留胰腺，切除脾血管和脾清扫No．10．和ll淋巴结合理可靠。     

PK刀在腹腔镜下早期子宫恶性肿瘤手术中的应用

目的探讨等离子刀(PK刀)在腹腔镜下广泛子宫切除术和盆腔淋巴结切除术治疗子宫恶性肿瘤中的应用价值。方法2003年1月~2006年12月,应用PK刀行腹腔镜下广泛子宫切除术和盆腔淋巴结切除术治疗30例经活检证实的早期子宫恶性肿瘤,其中子宫颈癌19例,子宫内膜癌11例。结果30例均在腹腔镜下完成手术,无一例中转开腹手术。手术时间(253.2±55.3)min,术中出血量(310.0±147.7)ml,淋巴结切除时间(73.5±23.6)min,淋巴结切除(17.0±6.2)枚,术后肛门排气时间(32.3±11.2)h,术后应用抗生素时间(5.5±1.5)d,术后住院(12±5)d。术中损伤膀胱1例,术后最高体温≥38.5℃3例,尿潴留4例,淋巴囊肿1例。结论PK刀作为兼备切割和止血的腹腔镜手术器械,其止血效果好,创伤小,具有较高的安全性,在子宫恶性肿瘤腹腔镜下行广泛子宫切除术和盆腔淋巴结切除术是安全、可行的。     

单孔+1腹腔镜全胃切除、D2淋巴结清扫术

因技术难度大、操作复杂及缺乏三角牵拉等原因,单孔+1腹腔镜全胃切除+D2淋巴结清扫+食管空肠吻合术存在技术上的挑战,目前尚未得到广泛应用。在此报道单孔+1腹腔镜全胃切除、D2淋巴结清扫术的初步经验。采用之前报道的单孔多通道通加1个戳孔(5 mm)的方式进行手术。全胃切除、D2淋巴结清扫的手术过程与传统腹腔镜手术方法相同。通过绕脐切口取出标本,使用体外空肠空肠吻合术和体内食管空肠吻合术完成Roux-en-Y重建(overlap)。手术时间198 min,出血量30 ml,没有观察到术中和术后并发症,清扫淋巴结数目50枚。术后排气时间、恢复流质饮食和住院时间分别为第2、4、7天。